- Poster presentation
- Open Access
Lynch syndrome-chasing a better ascertainment rate in British Columbia
Hereditary Cancer in Clinical Practice volume 8, Article number: P5 (2010)
With a population of approximately 4.380 million people and an estimated Lynch syndrome mutation prevalence of 1/531, there are an expected 8000 individuals with Lynch syndrome in British Columbia. The Hereditary Cancer Program (HCP) of the BC Cancer Agency (BCCA) has provided clinical testing for Lynch syndrome since 2004 to patients across the province. Currently, there are approximately 100 patients with confirmed Lynch syndrome mutations in the BCCA database. Potential obstacles in ascertaining Lynch syndrome through a traditional clinic-based approach include physician awareness of referral criteria, patient's lack of knowledge of cancer family history, patient compliance, and availability of tumour tissue for testing. Given these obstacles, a population based approach to identifying Lynch syndrome through incident testing of newly diagnosed colorectal cancers under age 50 by microsatellite instability testing (MSI) was launched in BC in June of 2008.
Chart review of a cohort of patients referred for genetic counselling at the RCP during 2004-2006 and a cohort of consecutive colorectal cancer cases referred directly for MSI testing to the BCCA Genetics Laboratory (June 2008-June 2009). Mutation prevalence and clinicopathologic characteristics will be compared between the two groups. Clinical and demographic characteristics of the groups will also be compared to non-referred cases diagnosed under 50 in the province.
Our previous clinic-based results showed a 14.3% prevalence of Lynch syndrome mutations among the index cases tested for whom results were available. 76% of tumour results were microsatellite stable and intact for MLH1 and MSH2 proteins. The sensitivity of the program's referral criteria was about 83.3% with an approximate confidence interval of 68.2%-96.8% and the positive predictive value was about 38.3% with an approximate confidence interval of 17.7%-60.0%. The prevalence of Lynch syndrome mutations dropped to 3.2% among all patients referred for genetic counseling. From July 2008 to July 2009, a total of 37 incident colorectal cases diagnosed under age 50 were referred directly to the BC Cancer Agency's cancer genetics lab. 73% were microsatellite stable while additional testing is underway on the 10 MSI high cases. Further comparisons between the groups will be presented.
Aside from becoming increasingly important for prognosis and predictive response to chemotherapy, population based MSI analysis on newly diagnosed colorectal cancer is expected to improve the rate of Lynch syndrome ascertainment in BC.